Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety

Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC), which was previously treated with non-steroidal aromat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Clin Oncol
Asıl Yazarlar: Riccardi, Ferdinando, Colantuoni, Giuseppe, Diana, Anna, Mocerino, Carmela, Cartenì, Giacomo, Lauria, Rossella, Febbraro, Antonio, Nuzzo, Francesco, Addeo, Raffaele, Marano, Ombretta, Incoronato, Pasquale, De Placido, Sabino, Ciardiello, Fortunato, Orditura, Michele
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2018
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6109668/
https://ncbi.nlm.nih.gov/pubmed/30155246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1672
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller